Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

The article compares two emerging biotech stocks: Intellia Therapeutics, which focuses on CRISPR gene-editing technology with promising Phase III trial data but significant losses and clinical risks, and Omeros, which recently achieved FDA approval for Yartemlea and posted its first commercial revenue of $9.89 million. While Intellia offers higher upside potential, Omeros is deemed the safer choice due to its transition to profitability, strong initial sales, and healthier balance sheet, despite trading at a premium valuation.

06/20/2026, 11:02 AM • The Motley Fool

This Stock Is Up 58% This Year. Is It too Late to Buy?

Intellia Therapeutics' stock has surged 58% year-to-date following positive phase 3 trial results for lonvo-z, a gene-editing treatment for hereditary angioedema. While lonvo-z shows promise with an 87% reduction in attacks, its commercial opportunity is limited to a small patient population (~7,000 in the U.S.), potentially generating $3.5 billion in lifetime sales. The company's more promising pipeline candidate, nex-z for transthyretin amyloidosis, won't show results until 2027. Investors should weigh significant clinical and regulatory risks against potential upside.

06/17/2026, 2:30 AM • The Motley Fool

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics announced positive Phase 3 HAELO trial results for lonvo-z, a CRISPR gene-editing treatment for hereditary angioedema (HAE). The treatment achieved an 87% reduction in monthly attacks versus placebo, with 62% of patients attack-free during the evaluation period. The company initiated a rolling BLA submission with the FDA and expects U.S. approval and launch in the first half of 2027.

06/13/2026, 7:30 AM • GlobeNewswire

1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't

Warren Buffett and Greg Abel's Berkshire Hathaway portfolio is notably absent from the healthcare sector, holding only DaVita and recently exiting UnitedHealth Group. The article argues investors should consider healthcare independently, as it offers opportunities across multiple investment styles—from high-growth pharma/biotech plays like Eli Lilly to dividend-paying stalwarts like Johnson & Johnson and Abbott Laboratories that provide steady earnings and income.

06/03/2026, 12:05 PM • The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood's Ark Invest added to positions in Shopify, Intellia Therapeutics, and GeneDX on Tuesday as all three stocks experienced significant declines. Shopify fell 16% after disappointing guidance despite strong quarterly results. GeneDX plummeted 49% following weak earnings and a major downward revision of full-year revenue guidance. Intellia Therapeutics had a modest 4% decline and remains supported by positive clinical trial data.

05/06/2026, 10:12 AM • The Motley Fool

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

Intellia Therapeutics priced an underwritten public offering of 16.7 million shares at $10.75 per share, generating approximately $180 million in gross proceeds. The offering is being managed by Jefferies, Goldman Sachs, and Citigroup. The company is a clinical-stage biopharmaceutical firm focused on CRISPR gene editing technologies.

04/29/2026, 7:00 AM • GlobeNewswire

S&P 500 Holds Near Highs Despite Oil Shock and Weak Breadth Data

U.S. equity markets held near record highs despite geopolitical tensions in the Middle East driving oil prices above $100/barrel. The collapse of U.S.-Iran negotiations triggered an energy shock, while major tech developments included OpenAI's partnership with Qualcomm on smartphone processors, Microsoft's loss of exclusive OpenAI access, and China's forced unwinding of Meta's AI acquisition. Consumer weakness emerged with Domino's cutting guidance, while positive credit metrics in auto lending and a gene-editing breakthrough in CRISPR therapy provided bright spots.

04/27/2026, 12:09 PM • Investing

3 Biotech Stocks That Could Benefit from the Patent Cliff

With a $300 billion patent cliff expected by 2030, biotech M&A activity is surging. The article identifies three gene-editing companies positioned as potential acquisition targets: CRISPR Therapeutics (established with commercial product), Intellia Therapeutics (pioneering in vivo CRISPR editing), and Beam Therapeutics (developing base editing technology). Each offers different risk/reward profiles for investors seeking exposure to one-time cure therapies.

04/27/2026, 11:29 AM • Investing

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics awarded inducement grants to 13 new employees on April 1, 2026, consisting of 67,150 restricted stock units vesting over three years under the company's 2024 Inducement Plan. The grants were approved by the compensation committee as a material inducement to employment in accordance with Nasdaq regulations.

04/03/2026, 4:05 PM • GlobeNewswire

This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy?

Intellia Therapeutics (NTLA), a gene-editing biotech backed by Cathie Wood's Ark Invest, has surged 41% this year following FDA approval to lift a clinical hold on one of its phase 3 studies for nex-z. While the company targets large addressable markets in rare diseases with potential peak sales in the billions, significant clinical and regulatory risks remain. The stock is considered very risky due to challenges in gene editing medicine adoption and potential regulatory setbacks.

02/07/2026, 9:05 AM • The Motley Fool

Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends

The global genome editing market is projected to grow from $9.39 billion in 2025 to $23.66 billion by 2031, driven by increased funding, CRISPR advancements, and AI integration. However, off-target effects and regulatory hurdles pose significant challenges. Key developments include AI-enhanced editing systems achieving 95% reduction in off-target effects and expansion into agricultural biotechnology.

01/22/2026, 4:56 AM • GlobeNewswire

Gene Editing Market Size to Surpass USD 42.13 Billion by 2034

The global gene editing market is projected to grow from $11.29 billion in 2025 to $42.13 billion by 2034, with a CAGR of 15.76%. North America dominates the market, while CRISPR-Cas9 technology leads in market share. Key drivers include potential medical and agricultural applications.

11/04/2025, 3:35 AM • GlobeNewswire

Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%

Intellia Therapeutics, a biotech company developing gene-editing therapies for rare diseases, faces significant risks after pausing clinical trials due to a patient experiencing liver damage. Despite potential blockbuster drug candidates, the stock's future remains uncertain.

11/02/2025, 9:25 AM • The Motley Fool

CRISPR Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 25+ Key Companies | DelveInsight

CRISPR therapies are showing significant potential with over 25 key companies developing 30+ pipeline therapies targeting genetic disorders, with promising clinical trials across various disease areas.

10/02/2025, 1:00 PM • GlobeNewswire

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia Therapeutics reported positive Phase 1 trial results for its gene editing therapy nex-z, showing sustained transthyretin protein reductions and potential clinical improvements in patients with hereditary ATTR amyloidosis. The company expects to complete Phase 3 trial enrollment in 2026 and potentially file for biologics license by 2028.

09/25/2025, 9:52 AM • Benzinga